• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.从患者白细胞分离样本中大规模清除CD25 +调节性T细胞。
J Immunother. 2005 Jul-Aug;28(4):403-11. doi: 10.1097/01.cji.0000170363.22585.5a.
2
Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity.人类CD4+CD25+调节性T细胞的功能检测揭示了其抑制活性的年龄依赖性丧失。
J Neurosci Res. 2003 Oct 15;74(2):296-308. doi: 10.1002/jnr.10766.
3
Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI).用于供体天然淋巴细胞输注(DILI)的临床规模单步CD4(+)和CD8(+)细胞清除
Bone Marrow Transplant. 2008 Apr;41(7):643-50. doi: 10.1038/sj.bmt.1705942. Epub 2007 Nov 26.
4
Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals.人类CD25 +调节性T细胞在健康、无过敏的个体中维持对镍的免疫耐受。
J Immunol. 2003 Dec 1;171(11):5760-8. doi: 10.4049/jimmunol.171.11.5760.
5
Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells.两种常见的人类Foxp3亚型中的任何一种的强制过表达都可以从CD4(+)CD25(-)细胞诱导出调节性T细胞。
Eur J Immunol. 2008 May;38(5):1381-90. doi: 10.1002/eji.200737590.
6
Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro.人CD4(+)CD25(+)胸腺细胞和外周血T细胞在体外具有免疫抑制活性。
Eur J Immunol. 2001 Apr;31(4):1247-54. doi: 10.1002/1521-4141(200104)31:4<1247::aid-immu1247>3.0.co;2-m.
7
Rapamycin promotes the enrichment of CD4(+)CD25(hi)FoxP3(+) T regulatory cells from naïve CD4(+) T cells of baboon that suppress antiporcine xenogenic response in vitro.雷帕霉素可促进从狒狒的初始CD4(+) T细胞中富集CD4(+)CD25(hi)FoxP3(+)调节性T细胞,这些细胞在体外可抑制抗猪异种反应。
Transplant Proc. 2009 Jan-Feb;41(1):418-21. doi: 10.1016/j.transproceed.2008.10.079.
8
Increased percentage of CD4+CD25+ regulatory T cells during septic shock is due to the decrease of CD4+CD25- lymphocytes.脓毒性休克期间CD4+CD25+调节性T细胞百分比增加是由于CD4+CD25-淋巴细胞减少所致。
Crit Care Med. 2004 Nov;32(11):2329-31. doi: 10.1097/01.ccm.0000145999.42971.4b.
9
Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.经体外扩增的食蟹猴 CD4+ CD25 Hi Treg 细胞可抑制食蟹猴抗猪 T 和 B 细胞免疫应答。
Xenotransplantation. 2012 Mar-Apr;19(2):102-11. doi: 10.1111/j.1399-3089.2012.00697.x.
10
Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.多克隆人CD4(+)CD25高调节性T细胞的大规模体外扩增
Blood. 2004 Aug 1;104(3):895-903. doi: 10.1182/blood-2004-01-0086. Epub 2004 Apr 15.

引用本文的文献

1
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.一项关于异基因干细胞移植后复发采用去除CD25/调节性T细胞的供体淋巴细胞输注的I期研究。
Haematologica. 2016 Oct;101(10):1251-1259. doi: 10.3324/haematol.2015.141176. Epub 2016 Jun 27.
2
Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.辅助免疫疗法改善高危儿童肉瘤的预后
Clin Cancer Res. 2016 Jul 1;22(13):3182-91. doi: 10.1158/1078-0432.CCR-15-2550. Epub 2016 Jan 28.
3
Translating Treg Therapy in Humanized Mice.在人源化小鼠中翻译调节性T细胞疗法。
Front Immunol. 2015 Dec 14;6:623. doi: 10.3389/fimmu.2015.00623. eCollection 2015.
4
Tumor infiltrating lymphocytes in ovarian cancer.卵巢癌中的肿瘤浸润淋巴细胞
Cancer Biol Ther. 2015;16(6):807-20. doi: 10.1080/15384047.2015.1040960. Epub 2015 Apr 20.
5
Novel immunotherapies for hematologic malignancies.血液系统恶性肿瘤的新型免疫疗法。
Immunol Rev. 2015 Jan;263(1):90-105. doi: 10.1111/imr.12245.
6
Isolation of highly suppressive CD25+FoxP3+ T regulatory cells from G-CSF-mobilized donors with retention of cytotoxic anti-viral CTLs: application for multi-functional immunotherapy post stem cell transplantation.从粒细胞集落刺激因子动员的供体中分离出高抑制性CD25+FoxP3+调节性T细胞并保留细胞毒性抗病毒细胞毒性T淋巴细胞:干细胞移植后多功能免疫治疗的应用
PLoS One. 2014 Jan 17;9(1):e85911. doi: 10.1371/journal.pone.0085911. eCollection 2014.
7
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.髓源性抑制细胞依附于生理性 STAT3 对 STAT5 的依赖性造血编程,建立了多种肿瘤介导的免疫逃避机制。
Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745.
8
Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.从黑色素瘤肿瘤浸润淋巴细胞培养物中富集 CD8+细胞可揭示用于过继细胞治疗的肿瘤反应性。
J Immunother. 2010 Jun;33(5):547-56. doi: 10.1097/CJI.0b013e3181d367bd.
9
The role of regulatory T cells in cancer.调节性 T 细胞在癌症中的作用。
Immune Netw. 2009 Dec;9(6):209-35. doi: 10.4110/in.2009.9.6.209. Epub 2009 Dec 31.
10
STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells.依赖于信号转导和转录激活因子3(STAT3)及信号转导和转录激活因子5(STAT5)的信号通路竞争性调控CD34阳性细胞向具有肿瘤能力的树突状细胞的全分化过程。
Blood. 2008 Sep 1;112(5):1832-43. doi: 10.1182/blood-2007-12-130138. Epub 2008 Jun 24.

本文引用的文献

1
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.非清髓性但淋巴细胞清除性化疗后采用过继性细胞转移疗法治疗难治性转移性黑色素瘤患者。
J Clin Oncol. 2005 Apr 1;23(10):2346-57. doi: 10.1200/JCO.2005.00.240.
2
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.CD4 +辅助性T细胞增强了CD8 + T细胞对肿瘤/自身抗原的免疫反应,而天然存在的调节性T细胞则对其产生阻碍。
J Immunol. 2005 Mar 1;174(5):2591-601. doi: 10.4049/jimmunol.174.5.2591.
3
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.汇池细胞、抑制细胞与抗原呈递细胞:淋巴细胞清除如何增强T细胞介导的肿瘤免疫治疗
Trends Immunol. 2005 Feb;26(2):111-7. doi: 10.1016/j.it.2004.12.003.
4
Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans.FOXP3信使核糖核酸的表达并不局限于人类的CD4+CD25+调节性T细胞。
Hum Immunol. 2005 Jan;66(1):13-20. doi: 10.1016/j.humimm.2004.05.016.
5
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.调节性T细胞可阻止对低免疫原性黑色素瘤的伴随肿瘤免疫。
J Exp Med. 2004 Sep 20;200(6):771-82. doi: 10.1084/jem.20041130.
6
Cancer immunotherapy: moving beyond current vaccines.癌症免疫疗法:超越现有疫苗
Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100.
7
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.卵巢癌中调节性T细胞的特异性募集促进免疫特权并预示生存率降低。
Nat Med. 2004 Sep;10(9):942-9. doi: 10.1038/nm1093. Epub 2004 Aug 22.
8
CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.急性感染后,CD4+ T细胞对于记忆性CD8+ T细胞的维持而非编程是必需的。
Nat Immunol. 2004 Sep;5(9):927-33. doi: 10.1038/ni1105. Epub 2004 Aug 8.
9
CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients.使用CliniMACS设备对异基因移植的外周血祖细胞进行CD34细胞分选:102例患者的临床结果
Br J Haematol. 2004 Aug;126(4):527-35. doi: 10.1111/j.1365-2141.2004.05062.x.
10
Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.表达Foxp3的CD4+CD25(高表达)调节性T细胞在人类转移性黑色素瘤淋巴结中占比过高,并抑制浸润性T细胞的功能。
J Immunol. 2004 Jul 15;173(2):1444-53. doi: 10.4049/jimmunol.173.2.1444.

从患者白细胞分离样本中大规模清除CD25 +调节性T细胞。

Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.

作者信息

Powell Daniel J, Parker Linda L, Rosenberg Steven A

机构信息

Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1201, USA.

出版信息

J Immunother. 2005 Jul-Aug;28(4):403-11. doi: 10.1097/01.cji.0000170363.22585.5a.

DOI:10.1097/01.cji.0000170363.22585.5a
PMID:16000960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1473966/
Abstract

The ability to selectively enrich or deplete T lymphocytes of specific phenotype and function holds significant promise for application in adoptive immunotherapy protocols. Although CD4+ T cells can have an impact on CD8+ T-cell effector function, memory, and maintenance, a subset of CD4+ T cells, CD25+ regulatory T cells (Treg), can regulate peripheral self tolerance and possess the ability to suppress antitumor responses. The authors report the ability to selectively deplete CD25+ Treg cells from patient leukapheresis samples using a clinical-grade, large-scale immunomagnetic system. Using leukapheresis samples containing up to 1.3 x 10(10) white blood cells, efficient depletion of Treg cells was measured by flow cytometric analysis of CD25 expression and FOXP3 expression on post-depletion products. Remnant CD25+ cells could not be detected in CD25-depleted products after short-term culture in IL-2 or enriched following secondary immunomagnetic selection for CD25+ cells, confirming that efficient depletion had occurred. In parallel to efficient enrichment of CD25- cells, immunomagnetic selection resulted in the recovery of Treg cells, since CD25+ lymphocytes removed during depletion were primarily composed of CD4+ T cells that expressed high levels of FOXP3 and possessed suppressive activity against autologous TCR-stimulated CD4+ CD25- T cells in vitro. These results show that selective separation of functional CD25+ Treg cells from large-scale samples can be performed in large scale under clinical-grade conditions with sufficient selection, recovery, viability, ability to expand, and function for potential use in adoptive immunotherapy.

摘要

选择性富集或去除特定表型和功能的T淋巴细胞的能力在过继性免疫治疗方案中的应用前景广阔。尽管CD4+ T细胞可影响CD8+ T细胞的效应功能、记忆和维持,但CD4+ T细胞的一个亚群,即CD25+调节性T细胞(Treg),可调节外周自身耐受性并具有抑制抗肿瘤反应的能力。作者报告了使用临床级大规模免疫磁选系统从患者白细胞分离样本中选择性去除CD25+ Treg细胞的能力。使用含有多达1.3×10¹⁰个白细胞的白细胞分离样本,通过对去除后产物上CD25表达和FOXP3表达进行流式细胞术分析来测定Treg细胞的有效去除情况。在IL-2中短期培养后,在CD25去除产物中未检测到残留的CD25+细胞,或在对CD25+细胞进行二次免疫磁选后未富集到CD25+细胞,这证实了有效去除已经发生。与高效富集CD25⁻细胞并行的是,免疫磁选导致了Treg细胞的回收,因为在去除过程中去除的CD25+淋巴细胞主要由表达高水平FOXP3并在体外对自体TCR刺激的CD4+ CD25⁻ T细胞具有抑制活性的CD4+ T细胞组成。这些结果表明,在临床级条件下,可以从大规模样本中大规模地选择性分离功能性CD25+ Treg细胞,且具有足够的分选、回收、活力、扩增能力和功能,可用于过继性免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/2722e9eaa474/nihms10147f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/fdef68220f0c/nihms10147f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/e968a7821808/nihms10147f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/b9bbc84a1f0d/nihms10147f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/2722e9eaa474/nihms10147f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/fdef68220f0c/nihms10147f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/e968a7821808/nihms10147f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/b9bbc84a1f0d/nihms10147f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c473/1473966/2722e9eaa474/nihms10147f4.jpg